Related Experiment Videos
Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency
M G Ausems1, K ten Berg, M A Kroos
1Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. M.G.E.M.Ausems@dmg.azu.nl
Community Genetics
|June 8, 2004
Summary
This study found no evidence of underdiagnosis for Glycogen Storage Disease type II (GSD II) in the Netherlands. The observed birth prevalence aligns with predictions, indicating accurate diagnosis rates for this rare genetic disorder.
Area of Science:
- Medical Genetics
- Rare Diseases
- Metabolic Disorders
Background:
- Glycogen Storage Disease type II (GSD II), also known as Pompe disease, is a rare genetic disorder.
- Accurate diagnosis and understanding of GSD II prevalence are crucial for patient management and research.
Purpose of the Study:
- To compare the diagnosed birth prevalence of GSD II with predicted frequencies.
- To assess whether GSD II is underdiagnosed in the Netherlands.
- To identify the medical disciplines involved in GSD II diagnosis.
Main Methods:
- Retrospective analysis of enzymatic GSD II diagnoses in the Netherlands (1972-1996).
- Calculation of age-specific diagnostic incidence and overall birth prevalence.
- Comparison of diagnosed prevalence with mutation screening predictions.
- Recording of referring clinicians' medical specializations.
Main Results:
- 154 GSD II cases diagnosed, including 11 prenatal.
- Birth prevalences: Infantile 1/101,000, Juvenile 1/720,000, Adult 1/53,000. Combined adult and infantile: 1/35,000.
- 82% of diagnoses occurred in university hospitals; infantile cases by pediatricians (71%), adult cases by neurologists (80%).
Conclusions:
- No evidence of GSD II underdiagnosis in the Netherlands; diagnosed prevalence matches predictions.
- Worldwide GSD II birth prevalence might exceed 1 in 100,000.
- GSD II diagnosis predominantly occurs in specialized university hospital settings.